Immunotherapy cost in Thailand

Immunotherapy cost in Thailand by medicine, indication, dose, and monitoring

Immunotherapy is not a single product or a guaranteed treatment. A responsible Thailand estimate names the immune drug, cancer indication, biomarker or clinical reason, dose or weight-based method, infusion interval, expected duration, combination drugs, blood tests, imaging, pharmacy, observation, and the response or toxicity events that could stop or change treatment. It also explains which immune complications need urgent care and how a home oncologist will continue monitoring.

How much does immunotherapy cost in Thailand?

A single outpatient immunotherapy infusion in Thailand may be planned at THB 99,000 to 330,000, approximately USD 3,000 to 10,000, depending on the agent and dose. An induction or combined course may total THB 660,000 to 2,475,000, around USD 20,000 to 75,000. Extended advanced treatment, combination regimens, or immune-related admission can reach THB 1,650,000 to 6,600,000+, about USD 50,000 to 200,000+. The hospital must confirm indication, availability, dose, and expected duration before a final quote.

USD illustrations use approximately THB 33 per USD, based on the Bank of Thailand exchange-rate context checked in July 2026. Drug prices can vary by originator or biosimilar status, dose, weight, interval, import or pharmacy supply, and currency. Confirm whether the estimate is controlled in THB or another currency.

Review cost scenarios Upload reports

Let Us Help You

Share the basics and the Virello team will guide you toward the next step.

Prefer email? Write to support@virellohealth.com.

Patient Name

Country

Phone Number

Describe The Current Medical Problem

Reviewed 2026-07-19

Clinical review: Virello Health Clinical Content Team · Editorial review: Virello Health Research Team

Billing context: THB and USD

The agent must be named

Checkpoint inhibitor, combination, route, dose, and interval make the difference between an informative estimate and a vague package.

Biomarkers are not optional decoration

Cancer type, stage, PD-L1 or another marker, previous therapy, and local approval determine whether immunotherapy is appropriate.

Immune toxicity can appear later

Lung, bowel, liver, skin, thyroid, adrenal, kidney, heart, nerve, or pituitary effects can need urgent treatment.

A response can change the plan

Imaging, symptoms, pseudoprogression, progression, and toxicity determine whether treatment continues, pauses, or changes.

Home monitoring is part of the journey

The patient needs a local oncologist, laboratory access, medicine list, and clear red-flag instructions after returning home.

Cost at a glance

Planning scenarios for immunotherapy in Thailand

The scenarios separate routine and complex pathways. They are not fixed packages and should be replaced by a report-led hospital estimate before travel.

Estimated immunotherapy cost scenarios in Thailand
Scenario	THB	USD	Patient and treatment context	Planning scope
Single outpatient infusion	THB 99,000 - 330,000	USD 3,000 - 10,000	A patient with a confirmed indication receiving one named immune medicine after laboratory and clinical review.	State medicine, dose, pharmacy, infusion, premedication, observation, and routine blood tests.
Induction or combined course	THB 660,000 - 2,475,000	USD 20,000 - 75,000	Several infusions or a combination with chemotherapy, targeted therapy, radiation, or another immune drug.	Include intervals, planned administrations, scans, blood tests, combination medicines, and response rules.
Extended or advanced treatment	THB 1,650,000 - 6,600,000+	USD 50,000 - 200,000+	Long-term disease-control treatment, multiple lines, high-cost combination, or care complicated by immune toxicity.	Use a duration range and contingency for steroids, endocrine care, hospital admission, and treatment interruption.

Usually included

Check the clinical package scope

Indication review

Diagnosis, stage, pathology, prior treatment, biomarker, organ function, autoimmune history, and treatment intent are assessed.

The prescribing oncologist should approve the indication.

Named immune treatment

Drug, dose, infusion interval, pharmacy preparation, nursing, observation, and premedication as specified.

Do not accept “immunotherapy package” without the agent.

Routine monitoring

Blood count, kidney and liver tests, thyroid or other endocrine checks, clinical review, and scheduled imaging when included.

Specialist tests may be separate.

Handover

Dose, date, reaction, response scan, next appointment, immune warning signs, steroid plan, and home clinician communication.

Treatment records should be released before departure.

Confirm separately

Charges that may sit outside the range

Drug and combination changes

Different agent, originator or biosimilar, added chemotherapy, targeted medicine, radiation, dose, or extra infusion.

Ask for a named alternative scenario.

Immune-related admission

Pneumonitis, colitis, hepatitis, nephritis, myocarditis, adrenal crisis, thyroid dysfunction, rash, neuropathy, or severe reaction.

Ask for emergency and ICU terms.

Additional investigations

Biomarker confirmation, autoimmune review, endocrine testing, CT, MRI, PET, biopsy, infection workup, or specialist consultations.

Not every test is routine for every cancer.

Home and travel costs

Hotel, companion, flights, translation, local laboratory, steroid or hormone replacement, home oncologist, and delayed return.

Immune toxicity can extend the stay.

Candidate context

Who may be considered and what else may be discussed

Immunotherapy may be appropriate for selected cancers and stages when pathology, biomarker, prior treatment, organ function, immune history, and clinical evidence support it. Some patients receive an immune drug alone; others receive a combination with chemotherapy, targeted treatment, radiation, or another checkpoint drug. Active autoimmune disease, organ transplantation, uncontrolled infection, steroids, and previous immune toxicity may affect the decision. A Thai oncologist should confirm the indication and access route rather than selling an attractive package based on the word “immunotherapy.”

Information that shapes suitability

Cancer indication

The cancer type, stage, treatment line, pathology, and evidence for the named agent should be documented.

Biomarker and response context

PD-L1 or another marker may help in selected cancers, but a marker is not a guarantee and is interpreted with the entire case.

Immune and organ history

Autoimmune disease, transplant, inflammatory bowel disease, lung disease, liver or kidney function, endocrine status, and prior immune reactions matter.

Monitoring capacity

The patient needs blood tests, imaging, thyroid or endocrine review, and access to urgent assessment for a new symptom.

Continuity plan

The same or a coordinated oncologist should define the next dose, treatment duration, steroid or replacement medicine, and home follow-up.

Alternatives or sequencing questions

Standard chemotherapy

Cytotoxic treatment may be used alone or with immune therapy when it is better supported for the cancer and clinical situation.

Targeted treatment

A driver mutation can support a specific oral or infusion medicine that may be preferable to an immune approach.

Surgery or radiation

Selected localized or symptomatic tumors may need local treatment before, instead of, or alongside systemic therapy.

Supportive care

Symptom control, transfusion, nutrition, pain treatment, and palliative support are valid components when disease control or tolerance is limited.

Procedure variations

Why the named procedure does not have one price

Technique, device, medicine, treatment extent, and prior care can change both the clinical plan and the estimate.

Single-agent checkpoint inhibitor

One named immune drug is given at a fixed or weight-based interval.

Check indication, dose, pharmacy, and duration.

Immune drug plus chemotherapy

An immune agent is paired with cytotoxic drugs for a selected cancer and stage.

Price both drug classes, administration, blood counts, and toxicity.

Dual immune blockade

Two immune medicines may be used in selected indications with more monitoring and toxicity complexity.

The quote should name both agents.

Adjuvant or maintenance therapy

Treatment continues after local therapy or response for a defined or response-dependent period.

The total course can extend beyond the initial travel.

Treatment after progression

A new line, combination, biopsy, radiation, or supportive approach may follow when the disease changes.

No package can promise a fixed duration.

City comparison

Cost and capability by city in Thailand

Only cities with evidence for the procedure should appear here. A city range does not prove that every hospital in that city can manage the same case complexity.

Estimated immunotherapy costs and planning context by city in Thailand
City	Local range	USD range	Capability context	Stay planning
Bangkok	THB 115,500 - 6,600,000+	USD 3,500 - 200,000+	Broad access to immune agents, cancer pharmacy, biomarker testing, day-care, inpatient care, and intensive support.	Confirm the product, indication, stock, and immune-toxicity pathway.
Chiang Mai	THB 108,900 - 5,610,000+	USD 3,300 - 170,000+	University and private hospitals may offer selected immune treatment with regional oncology follow-up.	Ask about urgent steroid, endocrine, lung, and ICU support.
Phuket	THB 115,500 - 5,280,000+	USD 3,500 - 160,000+	International service infrastructure is accessible, while medicine and specialist depth vary.	Verify pharmacy supply and oncology ownership before travel.
Pattaya and Chon Buri	THB 108,900 - 4,950,000+	USD 3,300 - 150,000+	Selected eastern hospitals may provide standard immune infusions and follow-up.	Confirm admission for colitis, pneumonitis, hepatitis, or endocrine crisis.
Khon Kaen	THB 105,600 - 4,620,000+	USD 3,200 - 140,000+	Regional tertiary services may suit stable indications with specialist oversight.	Make biomarker, drug stock, blood tests, and referral explicit.
Hat Yai and Songkhla	THB 105,600 - 4,620,000+	USD 3,200 - 140,000+	Southern care may support selected immune infusions and monitoring.	Ask about overnight oncology review and transfer if toxicity is severe.
Nakhon Ratchasima	THB 99,000 - 4,290,000+	USD 3,000 - 130,000+	Large regional hospitals may provide value for stable treatment and follow-up.	Confirm medicine continuity instead of assuming every agent is stocked.
Chiang Rai	THB 99,000 - 4,125,000+	USD 3,000 - 125,000+	Selected regional infusion services may be available after indication review.	Secure an escalation and emergency plan before treatment.
Udon Thani	THB 99,000 - 4,125,000+	USD 3,000 - 125,000+	Stable outpatient care may be feasible in a documented oncology program.	Check labs, endocrine monitoring, and home communication.
Rayong	THB 105,600 - 4,455,000+	USD 3,200 - 135,000+	Eastern corridor access may suit selected planned immune treatment.	A lower rate is not useful without reaction and admission capability.

Estimate variables

What can change the final hospital cost

Agent and dose

Drug class, originator or biosimilar, fixed or weight-based dose, interval, and pharmacy source drive the infusion cost.

Ask for the generic and brand.

Indication and biomarker

Cancer type, stage, prior line, PD-L1 or another marker, and evidence for combination treatment determine eligibility.

No biomarker guarantees response.

Duration and response

Adjuvant, induction, maintenance, progression, pseudoprogression, toxicity, and treatment pause affect the total.

Use a first-year scenario.

Immune monitoring

Thyroid, adrenal, liver, kidney, lung, heart, bowel, skin, and neurologic investigations can add cost.

A routine infusion package is not enough.

Travel and continuity

Hotel, companion, local labs, steroids, hormone replacement, emergency visits, and delayed flights add to the journey.

Keep a clinical contingency.

Medical cost breakdown

Before admission, in hospital, and after discharge

Diagnostics and preparation

Indication confirmation

Pathology, stage, prior treatment, biomarker, treatment line, and response or progression evidence.

An oncologist should authorize the treatment.

Baseline immune safety

CBC, kidney, liver, thyroid, endocrine, infection, autoimmune, ECG, lung, and other tests selected by the history.

Some results must be recent.

Response monitoring

CT, MRI, PET, examination, tumor markers, endocrine studies, or biopsy when the scan and symptoms disagree.

Immune response can be complex.

Admission and treatment

Outpatient infusion

Pharmacy preparation, infusion chair, nursing, premedication, observation, blood tests, and discharge advice.

Medicine may be billed separately.

Combined treatment

Immune drug with chemotherapy, targeted medicine, radiation, or another immune agent and its monitoring.

Request each component in THB.

Immune toxicity admission

Emergency assessment, imaging, cultures, steroids, hormone replacement, specialist review, ward, or ICU.

This is usually outside a routine package.

Recovery and follow-up

Between-infusion observation

Fatigue, fever, rash, diarrhea, cough, breathlessness, jaundice, headache, weakness, and endocrine symptoms need review.

A new symptom should be reported promptly.

Steroid and replacement care

Immune toxicity can require steroid taper, thyroid or adrenal replacement, glucose monitoring, and infection prevention.

Do not stop steroids suddenly.

Long-term follow-up

Scans, blood tests, endocrine, lung, liver, kidney, bowel, cardiac, and oncology review may continue after travel.

Home capacity should be confirmed.

Complete journey budget

Plan beyond the hospital invoice

Patient and attendant costs should be modeled separately from the medical estimate, with flexible dates and a contingency reserve.

Before travel

Pathology, biomarker, stage, prior treatment, autoimmune history, baseline tests, medicine list, visa, and hospital acceptance.

Avoid travel for an unconfirmed indication.

Infusion period

Day-care, housing, companion, transport, labs, pharmacy, translation, meals, and possible extra nights.

The risk window may occur after infusion.

Return reserve

Repeat blood tests, immune-toxicity visit, steroids, admission, changed flight, home oncologist, and next dose.

Return timing needs clinical clearance.

Country access

Rules and practical requirements to verify

Visa, donor, fertility, medicine, licensing, and treatment-access requirements can change. Confirm current rules with the relevant authority and treating hospital.

Confirm the medicine route

Ask the named hospital and pharmacy to confirm agent, indication, dose, Thai supply, approval or access route, and price validity.

Check immune-toxicity capability

Verify oncology, emergency, endocrine, gastroenterology, pulmonology, nephrology, cardiology, and ICU access as appropriate.

Review quality context

Healthcare Accreditation Institute information can help interpret hospital certification but does not guarantee response or access to a specific product.

Protect records and privacy

Agree pathology, biomarker, dose, reaction, scan, steroid, admission, consent, and cross-border handover documentation.

Use official travel guidance

Check Thailand e-Visa or embassy information and allow for delayed treatment, admission, or steroid taper.

Hospital selection

Compare capability before package price

Prescribing oncology team

Medical oncologist, pathology, pharmacy, nursing, and specialists aligned to the cancer and immune risks.

A coordinator should not prescribe.

Product and pharmacy

Exact agent, indication, dose, preparation, storage, stock, administration, and replacement plan.

Get it in writing before deposit.

Baseline and response testing

Biomarker, CBC, organ and endocrine tests, imaging, and review schedule are defined.

Old reports may be repeated.

Immune emergency support

Steroids, cultures, imaging, hormone replacement, specialist review, admission, and ICU escalation.

Ask for an after-hours number.

Continuity documentation

Infusion record, adverse effects, next dose, scan, medicine, red flags, and home clinician handover.

Obtain records before leaving.

Treating team

Specialists and support that may matter

Medical oncologist

Confirms cancer indication, agent, biomarker, treatment line, dose, duration, response, and toxicity decisions.

Oncology pharmacist and nurse

Validate product, prepare and administer the infusion, observe reactions, and teach immune warning signs.

Pathologist and radiologist

Provide the tissue, biomarker, stage, response, and progression evidence used for treatment.

Immune-toxicity specialists

Endocrine, lung, bowel, liver, kidney, cardiac, skin, and neurologic specialists may be needed when toxicity appears.

Home oncology team

Continues laboratory, imaging, steroids, replacement medicines, dose timing, and urgent assessment after return.

Treatment timeline

From report review to return-home follow-up

Remote eligibility review

Send pathology, stage, biomarker, previous treatment, autoimmune history, baseline tests, and medicines.

Drug confirmation

The Thai oncologist confirms the exact agent, indication, dose, interval, treatment goal, and estimated duration.

Baseline assessment

Blood, organ, endocrine, infection, cardiac, or lung tests are completed before infusion.

Infusion and observation

Pharmacy preparation, nursing, infusion, reaction monitoring, discharge education, and emergency contact follow.

Response or toxicity review

Scans and symptoms determine continuation; a new immune symptom may require treatment pause, steroids, or admission.

Home handover

Receive the dose record, adverse effects, next appointment, scan timing, steroid plan, red flags, and contact details.

Risks and edge cases

Events that can change the plan, stay, or cost

Pneumonitis

New cough, breathlessness, oxygen fall, fever, or chest imaging change can indicate immune lung inflammation.

Seek urgent assessment rather than waiting for the next infusion.

Colitis or hepatitis

Diarrhea, blood, abdominal pain, jaundice, dark urine, or abnormal liver tests may need steroids and admission.

Report early.

Endocrine crisis

Severe weakness, vomiting, low blood pressure, confusion, thyroid or adrenal disturbance can be serious.

Replacement treatment may continue long term.

Cardiac or neurologic toxicity

Chest pain, palpitations, fainting, weakness, numbness, or confusion require urgent specialist review.

Do not attribute all symptoms to fatigue.

Pseudoprogression or progression

Imaging can be difficult to interpret; symptoms, scans, and sometimes biopsy guide whether therapy continues.

One scan should not be oversold.

Treatment interruption

Toxicity, stock, travel, infection, or a changed indication can delay or stop the next dose.

Use a flexible journey budget.

Destination comparison

Compare India, Turkey, and Thailand for this procedure

The most suitable destination depends on the individual case, required team, treatment availability, travel route, legal eligibility, budget, and continuity after returning home.

Procedure planning comparison across India, Turkey, and Thailand
Decision factor	India	Turkey	Thailand	How to use this
Product access	Large oncology market with significant drug and brand variation.	Strong private access but product and package assumptions vary.	Selected immune agents are available through tertiary and private oncology services, subject to indication and supply.	Verify the exact product, not only the treatment label.
Price behavior	Per-infusion and drug-brand pricing may be separated.	Foreign-currency packages can hide duration and biosimilar terms.	THB infusion figures may exclude scans, immune toxicity, or combination treatment.	Request a first-year scenario.
Regional use	Stable infusions can be possible in Tier 2 centers under oncology oversight.	Regional standard treatment may be available after provider checks.	Regional care can suit selected stable patients with emergency referral support.	Immune-toxicity capability is more important than the headline city rate.
Continuity	Practical for South Asia, Gulf, and Africa.	Practical for Europe, Gulf, and Central Asia.	Practical for Southeast Asia and Asian routes.	Choose a destination with home endocrine and oncology support.

Decision guidance

When Thailand may fit and when to keep comparing

Thailand may fit when

The exact agent and indication are verified, baseline tests are reviewed, pharmacy stock is confirmed, and immune-toxicity care is available.

Keep comparing when

A provider will not name the medicine, relies on a biomarker slogan, cannot explain immune emergencies, or promises guaranteed response.

Regional care may fit when

The patient is stable, the product is stocked, laboratory and oncology review are reliable, and a tertiary escalation route exists.

Urgent local care comes first when

There is breathlessness, chest pain, severe diarrhea, jaundice, fainting, confusion, or a serious infusion reaction.

Reports for review

Prepare a case file before requesting estimates

Prepare pathology, stage scans, biomarker results, prior treatment, autoimmune and transplant history, baseline blood and endocrine tests, medicines, allergies, immune-toxicity history, and treatment goals. Ask the Thai provider for a written plan naming agent, indication, dose, interval, duration, combination therapy, tests, emergency terms, THB validity, travel timing, and home handover.

Upload medical reports

Eligibility file

Cancer evidence

Include pathology, stage, prior treatment, biomarker, response or progression, and reason immune treatment is proposed.

Baseline organs

Provide CBC, kidney, liver, thyroid, endocrine, infection, cardiac, lung, and other relevant tests.

Immune history

Document autoimmune disease, transplant, inflammatory bowel disease, previous steroids, and earlier immune toxicity.

Current medicines

List cancer drugs, immunosuppressants, steroids, replacement hormones, anticoagulants, supplements, and allergies.

Travel and continuity file

Travel documents

Share passport, visa, companion, language, housing, insurance, mobility, and flexible return information.

Treatment support

Include local laboratory, oncologist, emergency hospital, pharmacy, and caregiver details.

Red flags

Record cough, diarrhea, jaundice, rash, weakness, endocrine symptoms, chest symptoms, and fever instructions.

Previous reactions

Provide dates, grade, treatment, steroid dose, admission, and whether immunotherapy was stopped or restarted.

Quote questions

Product

Ask for generic, brand, dose, interval, originator or biosimilar, pharmacy, and supply period.

Monitoring

Confirm labs, endocrine, imaging, infusion, observation, and specialist review.

Toxicity

Request emergency, steroid, hormone replacement, ward, ICU, and delayed-dose terms.

Handover

Agree infusion record, next dose, scan, prescriptions, red flags, privacy, and cancellation terms.

Common questions

Questions about cost, travel, and follow-up

What is immunotherapy cost in Thailand?

A single infusion may be THB 99,000 to 330,000, while an extended or combined course can range from THB 660,000 to 6,600,000 or more depending on the agent and duration.

Which immunotherapy drug will I receive?

The treating oncologist should name the generic and brand, indication, dose, interval, and access route. “Immunotherapy” alone is not enough.

Do I need a biomarker?

Some cancers use PD-L1 or another marker, while others rely on cancer type, stage, prior treatment, and clinical evidence. The oncologist decides.

Does immunotherapy cost include chemotherapy?

Not unless the quotation names both drug classes, doses, cycles, administration, and monitoring.

What are important immune side effects?

Breathlessness, severe diarrhea, jaundice, rash, weakness, chest symptoms, endocrine crisis, kidney changes, and neurologic symptoms need prompt medical review.

Can I continue treatment at home?

Often it can be coordinated, but product access, interval, local oncologist, laboratory, scans, and emergency support must be confirmed.

How long does immunotherapy continue?

It may be a defined adjuvant course or continue while beneficial and tolerated; progression and toxicity can change the duration.

Can a Tier 2 city provide immunotherapy?

Selected stable cases may fit when the product is stocked, oncology review is available, labs are reliable, and tertiary escalation is ready.

Can I fly after an infusion?

Possibly, but symptoms, reaction history, blood tests, treatment timing, and the oncologist’s clearance determine safety.

What records should I send?

Send pathology, stage, biomarker, prior therapy, autoimmune history, baseline tests, medicines, and previous immune reactions.

Review and sources

How this guide was prepared

The ranges distinguish a single named infusion, an induction or combined course, and extended advanced treatment. The working conversion is approximately THB 33 per USD using the Bank of Thailand source checked in July 2026. The estimate expands beyond drug price to biomarker review, baseline tests, pharmacy, scans, endocrine monitoring, immune toxicity, steroids, admission, travel, and home follow-up. The treating oncologist and hospital pharmacy must issue the final agent-specific estimate.

This page is educational and cannot prescribe immunotherapy, establish eligibility, guarantee a response, confirm product availability, or certify a hospital’s current authorization. An oncologist should review the cancer, biomarker, immune history, and organ function. Breathlessness, severe diarrhea, jaundice, chest symptoms, fainting, confusion, or a serious reaction requires urgent local medical care.

Related planning